PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.

Abstract In this study, enzyme-linked immunosorbent assay has been used to examine the frequencies of serum autoantibodies against two candidate tumor-associated antigens intensively selected from the Human Protein Atlas database, in combination with 13 tumor-associated antigens available from our lab in sera from 44 OC patients and 50 normal healthy controls. Conventional evaluation (mean + 3SD as the cutoff value to determine a positive reactivity), receiver operating characteristic curve analyses, and classification tree analysis were further used to evaluate the diagnostic performance of autoantibodies against these tumor-associated antigens (anti-tumor-associated antigens) in ovarian cancer. For single anti-tumor-associated antigen, when the cutoff values were set as mean + 3SD of normal healthy controls, NPM1, MDM2, PLAT, p53, and c-Myc could achieve sensitivity higher than 20% at 98% specificity. Combinational utilization of autoantibodies against MDM2, PLAT, NPM1, 14-3-3 Zeta, p53, and RalA achieved the optimal diagnostic performance with 72.7% sensitivity at 96% specificity. Receiver operating characteristic curve analysis showed that the area under the receiver operating characteristic curves of autoantibodies against c-Myc, NPM1, MDM2, p16, p53, and 14-3-3 Zeta were greater than 0.80. This indicated that these tumor-associated antigens held high potential to serve as diagnostic biomarkers in ovarian cancer detection. Decision tree analysis indicated that anti-c-Myc held high potential in the detection of ovarian cancer. Further studies are warranted to validate the diagnostic performance of these anti-tumor-associated antigens with high area under the receiver operating characteristic curve, including autoantibodies against c-Myc, MDM2, PLAT, NPM1, 14-3-3 Zeta, p53, and RalA.
PMID
Related Publications

Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer.

Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.

Comparison of candidate serologic markers for type I and type II ovarian cancer.

Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma.

Detection of autoantibodies to a panel of tumor-associated antigens for the diagnosis values of gastric cardia adenocarcinoma.

Authors

Mayor MeshTerms
Keywords

Tumor-associated antigen

autoantibody

biomarker

immunodiagnosis

micro-array

ovarian cancer

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28618923
OWN - NLM
STAT- MEDLINE
DA  - 20170616
DCOM- 20170705
LR  - 20170705
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Serum autoantibodies against a panel of 15 tumor-associated antigens in the
      detection of ovarian cancer.
PG  - 1010428317699132
LID - 10.1177/1010428317699132 [doi]
AB  - In this study, enzyme-linked immunosorbent assay has been used to examine the
      frequencies of serum autoantibodies against two candidate tumor-associated
      antigens intensively selected from the Human Protein Atlas database, in
      combination with 13 tumor-associated antigens available from our lab in sera from
      44 OC patients and 50 normal healthy controls. Conventional evaluation (mean +
      3SD as the cutoff value to determine a positive reactivity), receiver operating
      characteristic curve analyses, and classification tree analysis were further used
      to evaluate the diagnostic performance of autoantibodies against these
      tumor-associated antigens (anti-tumor-associated antigens) in ovarian cancer. For
      single anti-tumor-associated antigen, when the cutoff values were set as mean +
      3SD of normal healthy controls, NPM1, MDM2, PLAT, p53, and c-Myc could achieve
      sensitivity higher than 20% at 98% specificity. Combinational utilization of
      autoantibodies against MDM2, PLAT, NPM1, 14-3-3 Zeta, p53, and RalA achieved the 
      optimal diagnostic performance with 72.7% sensitivity at 96% specificity.
      Receiver operating characteristic curve analysis showed that the area under the
      receiver operating characteristic curves of autoantibodies against c-Myc, NPM1,
      MDM2, p16, p53, and 14-3-3 Zeta were greater than 0.80. This indicated that these
      tumor-associated antigens held high potential to serve as diagnostic biomarkers
      in ovarian cancer detection. Decision tree analysis indicated that anti-c-Myc
      held high potential in the detection of ovarian cancer. Further studies are
      warranted to validate the diagnostic performance of these anti-tumor-associated
      antigens with high area under the receiver operating characteristic curve,
      including autoantibodies against c-Myc, MDM2, PLAT, NPM1, 14-3-3 Zeta, p53, and
      RalA.
FAU - Sun, Hao
AU  - Sun H
AD  - 1 Affiliated Cancer Hospital of Zhengzhou University, College of Public Health,
      Zhengzhou University, Zhengzhou, China.
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
FAU - Shi, Jian-Xiang
AU  - Shi JX
AD  - 1 Affiliated Cancer Hospital of Zhengzhou University, College of Public Health,
      Zhengzhou University, Zhengzhou, China.
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
FAU - Zhang, Hong-Fei
AU  - Zhang HF
AD  - 1 Affiliated Cancer Hospital of Zhengzhou University, College of Public Health,
      Zhengzhou University, Zhengzhou, China.
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
FAU - Xing, Meng-Tao
AU  - Xing MT
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
FAU - Li, Pei
AU  - Li P
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
AD  - 3 Henan Academy of Medical and Pharmaceutical Sciences and Academy of Medical
      Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Dai, Li-Ping
AU  - Dai LP
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
AD  - 3 Henan Academy of Medical and Pharmaceutical Sciences and Academy of Medical
      Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Luo, Cheng-Lin
AU  - Luo CL
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
FAU - Wang, Xiao
AU  - Wang X
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
AD  - 3 Henan Academy of Medical and Pharmaceutical Sciences and Academy of Medical
      Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Wang, Peng
AU  - Wang P
AD  - 1 Affiliated Cancer Hospital of Zhengzhou University, College of Public Health,
      Zhengzhou University, Zhengzhou, China.
AD  - 3 Henan Academy of Medical and Pharmaceutical Sciences and Academy of Medical
      Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Ye, Hua
AU  - Ye H
AD  - 1 Affiliated Cancer Hospital of Zhengzhou University, College of Public Health,
      Zhengzhou University, Zhengzhou, China.
AD  - 3 Henan Academy of Medical and Pharmaceutical Sciences and Academy of Medical
      Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Li, Liu-Xia
AU  - Li LX
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
AD  - 3 Henan Academy of Medical and Pharmaceutical Sciences and Academy of Medical
      Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Zhang, Jian-Ying
AU  - Zhang JY
AD  - 1 Affiliated Cancer Hospital of Zhengzhou University, College of Public Health,
      Zhengzhou University, Zhengzhou, China.
AD  - 2 Department of Biological Sciences, The University of Texas at El Paso, El Paso,
      TX, USA.
AD  - 3 Henan Academy of Medical and Pharmaceutical Sciences and Academy of Medical
      Sciences, Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Antigens, Neoplasm/*blood
MH  - Autoantibodies/*blood
MH  - Biomarkers, Tumor/*blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Neoplasm Proteins/blood
MH  - Ovarian Neoplasms/*blood/pathology
OTO - NOTNLM
OT  - Tumor-associated antigen
OT  - autoantibody
OT  - biomarker
OT  - immunodiagnosis
OT  - micro-array
OT  - ovarian cancer
EDAT- 2017/06/18 06:00
MHDA- 2017/07/06 06:00
CRDT- 2017/06/17 06:00
AID - 10.1177/1010428317699132 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317699132. doi: 10.1177/1010428317699132.